Featured news | Nanologica

Nanologica receives order for purification media, MSEK 3.6 value

29 November, 2023

NANOLOGICA RECEIVES ORDER OF PURIFICATION MEDIA WORTH APPROX. MSEK 3.6 Nanologica expands its product portfolio of purification medias for preparative chromatography and has received a trial order worth approximately MSEK 3.6 from a customer in Asia. Product development of this purification media, NLAB Siv™, has been conducted together with a customer who has a number of launched pharmaceutical products. NLAB Siv™ is a non-silica-based purification media for preparative chromatography and manufacturing takes place at a

InFocus-intervju Redeye Life Science Day 2023

27 November, 2023

InFocus-intervju med Andreas Bhagwani på Redeye Life Science Day 23 november 2023.

Redeye Life Science Day 2023

3 November, 2023

Nanologica will participate in Redeye Life Science Day 2023. CEO Andreas Bhagwani will take part of an In Focus interview at 09.20. The interview will be broadcasted live on this link. For further information about the event and how to attend in person, please visit Redeyes event site.

Interview with CEO Andreas Bhagwani on the Interim Report for Q3 2023

27 October, 2023

Interim Report for Q3 2023 Published

27 October, 2023

Read the report here

Interview with CEO Andreas Bhagwani on first large-scale delivery

18 October, 2023

Nanologica’s CEO Andreas Bhagwani interviewed by Redeye analyst Filip Einarsson regarding Nanologica’s first large-scale delivery to an insulin manufacturer for evaluation in production and what this means for the company going forward. Watch the video here (in Swedish).

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.